D-0776-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0776-2021 was initiated by Teva Pharmaceuticals USA on Jul 29, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate. The recall status is terminated (terminated Nov 4, 2022). Affected quantity: 4,992 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 8, 2021
Initiation Date
Jul 29, 2021
Termination Date
Nov 4, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4,992 bottles

Product description

Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc. Fort Lauderdale, FL 33314, NDC 57237-266-01

Reason for recall

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Distribution pattern

Product was distributed nationwide.

Code information

1408824A, exp. date 08/2023 (labeler - Rising)

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0776-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0776-2021. Report a data issue: hello@regdatalab.com.